Related Experiment Video
Updated: Apr 10, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses
Diana Ferraro1, Vincenzo G Mirante, Luisa Losi
1*Neurology Unit, Department of Neurosciences ‡Pathology Institute §Gastroenterology Unit, University of Modena and Reggio Emilia †Internal Medicine and Gastroenterology Unit, Nuovo Ospedale Civile Sant'Agostino Estense, Modena, Italy.
Abstract:
High-dose, intravenous methylprednisolone (MP) is the only recommended first-line treatment for multiple sclerosis relapses. However, there are increasing reports on liver toxicity induced by this treatment regimen. We report of 4 multiple sclerosis patients with no history of viral/metabolic liver disorders or alcohol/hepatotoxic drug intake, who developed hypertransaminasaemia following intravenous MP. In 2 of the patients, liver biopsy showed periportal fibrosis, piecemeal necrosis, and inflammatory cell infiltrates. A rechallenge test confirmed a causal association in 1 case. MP-induced liver toxicity may be more frequent than commonly thought and it is important to report this adverse reaction, which is potentially lethal, and to raise awareness on the potential hepatotoxicity of corticosteroid pulses.
Insights
High-dose intravenous methylprednisolone (MP) can cause liver damage in multiple sclerosis patients. This potentially lethal adverse reaction may be more common than previously recognized.
Area of Science:
- Neurology
- Hepatology
- Clinical Pharmacology
Background:
- Intravenous methylprednisolone (MP) is a standard first-line therapy for multiple sclerosis (MS) relapses.
- Concerns exist regarding potential liver toxicity associated with this treatment.
Observation:
- Four multiple sclerosis patients without pre-existing liver conditions or risk factors developed elevated liver enzymes after IV MP treatment.
- Liver biopsies in two patients revealed significant histological changes, including fibrosis and necrosis.
Findings:
- A causal link between MP administration and hypertransaminasaemia was confirmed in one patient via rechallenge.
- Hepatotoxicity is a potential adverse effect of high-dose intravenous MP therapy in MS patients.
Implications:
- Increased awareness of MP-induced liver toxicity is crucial for clinicians managing MS patients.
- Monitoring liver function may be warranted during or after corticosteroid pulse therapy.
- This highlights the importance of reporting potentially lethal adverse drug reactions.
Related Concept Videos
Drug toxicity: Idiosyncratic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Toxicity: Allergic Reactions
Drug Toxicity: Dose-Dependent Reactions
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

